Elizabeth Masson-Hurlburt
Corporate Officer/Principal bij CORMEDIX INC.
Vermogen: 192 483 $ op 31-03-2024
Actieve functies van Elizabeth Masson-Hurlburt
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| CORMEDIX INC. | Corporate Officer/Principal | - | - |
| Chief Tech/Sci/R&D Officer | 01-03-2018 | - |
Loopbaan van Elizabeth Masson-Hurlburt
Eerdere bekende functies van Elizabeth Masson-Hurlburt
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| NEUROBO PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | 01-08-2016 | 01-03-2018 |
Opleiding van Elizabeth Masson-Hurlburt
| Bay Path College | Undergraduate Degree |
Statistieken
Internationaal
| Verenigde Staten | 4 |
Operationeel
| Chief Tech/Sci/R&D Officer | 2 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoraal
| Health Technology | 3 |
| Consumer Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 1 |
|---|---|
| CORMEDIX INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Gemphire Therapeutics, Inc.
 Gemphire Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Gemphire Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics of dyslipidemia, as well as non-alcoholic fatty liver disease. It offers a small molecule formulated as a tablet product under the Gemcabene brand. The company was founded by Charles L. Bisgaier and David Lowenschuss on October 30, 2014 and is headquartered in Livonia, MI. | Health Technology |
